Zentalis Pharmaceuticals remains focused on developing azenosertib, an oral WEE1 inhibitor targeting Cyclin E1-positive PROC patients, with Phase 2 topline data expected by late 2026. Historical setbacks have led to persistent net losses exceeding $100 million annually, though costs declined in 2025 following strategic restructuring. The pathway to regulatory approval hinges on data from the DENALI Part 2 trial, with a confirmatory Phase 3 study planned. While the company’s proprietary biomarker-driven approach offers differentiation, reliance on a single product candidate and third-party manufacturers presents financial and operational challenges. Coverage, reimbursement, and healthcare compliance risks also loom over prospective commercialization.